We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

National Survey on Dyslipidemic Patients (PRYSME)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00701402
First Posted: June 19, 2008
Last Update Posted: August 6, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.

Condition
Dyslipidemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • time to lipid-lowering drug implementation (immediately, treatment within a period 0-3 month and > 3 month, according to the cardiovascular risk level, (0 risk factor, 1 risk factor, 2 risk factors, ≥ 3 risk factors, secondary prevention). [ Time Frame: Once ]

Enrollment: 3655
Study Start Date: June 2008
Study Completion Date: January 2009
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First three consecutive dyslipidemic patients seen by GP
Criteria

Inclusion Criteria:

  • Diagnosis of dyslipemia made less than 2 years
  • Treated by a lipid-lowering drug
  • Agree to take part in the survey

Exclusion Criteria:

  • Patient included in a clinical trial
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00701402


  Show 1207 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne AstraZeneca
  More Information

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00701402     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2007/9
First Submitted: June 18, 2008
First Posted: June 19, 2008
Last Update Posted: August 6, 2009
Last Verified: August 2009

Keywords provided by AstraZeneca:
time to lipid-lowering drug implementation
dyslipidemic patients

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents